Paula Kujala
YOU?
Author Swipe
View article: Risk factors for low‐risk prostate cancer: A retrospective cohort study within the <scp>FinRSPC</scp> trial
Risk factors for low‐risk prostate cancer: A retrospective cohort study within the <span>FinRSPC</span> trial Open
Overdiagnosis of low‐risk prostate cancer (PC), often accompanied by overtreatment, remains an important harmful consequence of prostate‐specific antigen (PSA)‐based screening. Although PSA screening can reduce PC mortality and metastatic …
View article: Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer
Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer Open
In this study, we analyzed prostate cancer deaths in Finnish men with low initial prostate-specific antigen (PSA) levels. We found that the risk of prostate cancer death increases in relation to PSA, especially in younger men. Screening mi…
View article: Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI
Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI Open
Importance Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important. Objective To describe rates of low-grade (grade group 1) and hi…
View article: Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) Open
View article: Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine Open
View article: Appendix Table 1. from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Appendix Table 1. from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Open
Results of the case-control study
View article: Appendix Table 1. from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Appendix Table 1. from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Open
Results of the case-control study
View article: Data from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Data from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Open
Purpose:The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence…
View article: Data from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)
Data from The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC) Open
Purpose:The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer mortality by PSA-based screening. The aim of the study is to evaluate screening effect on prostate cancer incidence…
View article: Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours
Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours Open
Melanoma is a highly metastatic tumour originating from neural crest-derived melanocytes. The aim of this study was to analyse the expression of neuron navigator 3 (NAV3) in relation to membrane type-1 matrix metalloproteinase MMP14, a maj…
View article: Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/<scp>mL</scp>: The Finnish Randomized Study of Screening for Prostate Cancer
Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/<span>mL</span>: The Finnish Randomized Study of Screening for Prostate Cancer Open
Prostate‐specific antigen (PSA)‐based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low‐risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 n…
View article: Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study Open
Objectives To evaluate the feasibility of a population‐based screening trial using prostate‐specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimizing overdiagnosis, while retaining …
View article: Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine Open
View article: Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation Open
We developed and validated a prognostic index to predict survival from prostate cancer (PCa) based on the Finnish randomized screening trial (FinRSPC). Men diagnosed with localized PCa (N = 7042) were included. European Association of Urol…
View article: Number of screening rounds attended and incidence of high‐risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
Number of screening rounds attended and incidence of high‐risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) Open
Background The European Randomized Study of Screening for Prostate Cancer has shown a 20% reduction in prostate cancer (PC) mortality by prostate‐specific antigen–based screening. In addition, screening has been shown to reduce the risk of…
View article: Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland
Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland Open
Introduction Since 2012, cervical cancer screening has been conducted with a primary high‐risk human papillomavirus (hrHPV) test and conventional cytology triage in the city of Tampere, Finland. The women who were screened with the hrHPV t…
View article: Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer Open
Background The long‐term health‐related quality of life (HRQOL) impacts of PCa screening have not been adequately evaluated. We aimed to compare the generic and disease‐specific health‐related quality of life (HRQOL) among men with prostat…
View article: Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data Open
In contrast to earlier studies which have used modelling to perform cost-effectiveness analysis, this study links data from a randomised controlled trial with register data from nationwide registries to reveal new evidence on costs, effect…
View article: A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer Open
View article: Bias‐corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer
Bias‐corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer Open
More information is needed about effects of prostate‐specific antigen (PSA) screening for informed decision making. The objective of our study is to evaluate the effects of an implemented screening decision on the risk of prostate cancer (…
View article: Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy
Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy Open
The findings do not support cholesterol as a risk factor for PCa severity or prognosis after prostatectomy. Cholesterol decline by statin treatment was associated with improved recurrence-free survival compared to statin users whose choles…
View article: A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Open
View article: Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology
Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology Open
Advances in prostate cancer biology and diagnostics are dependent upon high-fidelity integration of clinical, histomorphologic, and molecular phenotypic findings. In this study, we compared fresh frozen, formalin-fixed paraffin-embedded (F…
View article: In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium
In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium Open
View article: A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale Open
View article: Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer Open
A large proportion of men in the control arm had undergone a prostate specific antigen test during the 15-year followup. Contamination is likely to dilute differences in prostate cancer mortality between the arms in the Finnish screening t…
View article: Pariisin luokitus - uusi virtsan sytologian luokitusjärjestelmä
Pariisin luokitus - uusi virtsan sytologian luokitusjärjestelmä Open
Virtsan sytologiseen irtosolunäytetutkimukseen on tullut uusi luokitusjärjestelmä TPS eli Pariisin luokitus. Uusi luokitus jakaa solumuutokset pahanlaatuisuudeltaan korkea-asteiseen uroteelikarsinomaan viittaaviin muutoksiin sekä lievempii…
View article: Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer
Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer Open
Prostate cancer (PC) screening remains controversial. We investigated whether screening reduces the difference in prostate cancer risk by socioeconomic status (SES). In 1996-2011, a total of 72,139 men from the Finnish Randomized Study of …
View article: Human papillomavirus test with cytology triage in organized screening for cervical cancer
Human papillomavirus test with cytology triage in organized screening for cervical cancer Open
Introduction In randomized studies, testing for high‐risk ( HR ) human papillomavirus (hrHPV) has been more sensitive than conventional cytology in detecting cervical intraepithelial neoplasia ( CIN ). The aim of this study was to evaluate…
View article: Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study
Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study Open